Free Trial
→ Top Trader Reveals Stunning Black Friday Deal (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ALZN

Alzamend Neuro Q2 2027 Earnings Date & Estimates

Alzamend Neuro logo
$1.26 -0.04 (-2.77%)
As of 12:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alzamend Neuro is estimated to report Q2 2027 earnings on Tuesday, December 8, 2026. The conference call is scheduled for December 10, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alzamend Neuro in Q2 2027

Alzamend Neuro is expected to post earnings of -$0.23 per share. In the same quarter a year earlier Alzamend Neuro reported -$0.30 per share. Alzamend Neuro last reported on September 10, 2026, posting -$0.68 per share and missing the -$0.56 consensus estimate. Alzamend Neuro has beaten the consensus EPS estimate in 4 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$0.23
Prior-Year EPS
-$0.30

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.68 (Missed by -$0.12)
EPS Beat Rate
4 of last 7 quarters

Prepare for the Q2 2027 Call

Alzamend Neuro Q2 2027 Earnings FAQ

Alzamend Neuro (NASDAQ:ALZN) is estimated to report Q2 2027 earnings on Tuesday, December 8, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Alzamend Neuro's Q2 2027 earnings conference call is scheduled for Thursday, December 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alzamend Neuro to post earnings of -$0.23 per share for Q2 2027.

Alzamend Neuro Earnings Headlines

Alzamend Neuro Highlights Early AL001 Brain Lithium Data
September 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alzamend-neuro-highlights-early-al001-brain-lithium-data?utm_source=marketbeat.com&utm_medium=referral
Alzamend Regains Compliance With Nasdaq Equity Requirement
September 17, 2026  |  rttnews.comhttps://www.rttnews.com/3691849/alzamend-regains-compliance-with-nasdaq-equity-requirement.aspx
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
November 13 at 1:00 AM  |  Profits Run (Ad)
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
August 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alzamend-neuros-phase-12a-lithium-neuroimaging-data-accepted-for-poster-presentation-at-neuroscience-2026-in-washington-dc-302856333.html
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
August 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alzamend-neuros-phase-12a-lithium-imaging-data-accepted-for-oral-presentation-at-ismrm-workshop-on-x-nuclei-mr-in-barcelona-spain-302853994.html
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
August 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alzamend-neuro-announces-initial-closing-of-securities-purchase-agreement-with-ault-lending-302842236.html
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN) (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and neuropsychiatric diseases, with an emphasis on Alzheimer’s disease and related dementia. The company’s research is intended to address cognitive decline and other disease-related symptoms through therapies designed to affect biological processes associated with brain function.

Alzamend Neuro’s lead development program is AL001, an investigational lithium-based product candidate being studied for potential use in the treatment of Alzheimer’s disease. The company is also advancing AL002, an additional investigational product candidate intended to address Alzheimer’s disease through a different therapeutic approach. These candidates remain in development and have not been approved for commercial use.

The company was established to pursue pharmaceutical technologies for central nervous system disorders and is conducting its development activities through clinical research and collaborations. As a development-stage biotechnology company, Alzamend Neuro does not currently have an established portfolio of commercially marketed products. Information about its operations and clinical programs is primarily provided through its public regulatory filings and corporate disclosures.

View Alzamend Neuro Profile
Earnings Tools